HOME ·

IMMUNEONCO-B

IMMUNEONCO-B (01541.HK): First patient dosed in Phase II trial of IMM2510 plus IMM27M as first-line treatment for advanced HCC
Tags：
IMMUNEONCO-B01541.HKClinical Trial
2026-08-27
IMMUNEONCO-B (01541.HK): First patient dosed in IMC-003 PAH trial, SAD and MAD dose cohorts fully enrolled
Tags：
IMMUNEONCO-B01541.HKR&D Progress
2026-08-25
IMMUNEONCO-B (01541.HK): Subsidiary Yiming Kaier receives RMB 50 million capital increase from Shengke Qihang and other investors; Company to hold approximately 68.34% upon completion
Tags：
IMMUNEONCO-B01541.HK
2026-08-07
IMMUNEONCO-B (01541.HK): First Patient Dosed in Phase II/III Trial of IMM0306 for IgG4-Related Disease
Tags：
IMMUNEONCO-B01541.HKfirst patient dosing
2026-07-10